Mesenchymal Stem Cells Market Advances and Applications – Market Growth and Future Analysis: ResearchMoz

ResearchMoz.us has announced a new market research study Titled ‘Applications of Mesenchymal Stem Cells Market: Global Industry Size, Shares, Trends, Market Opportunities and Forecast’ to its vast internet repository of market intelligence reports.


Albany, NY, March 22, 2016 (GLOBE NEWSWIRE) -- The report explores the recent advancements in mesenchymal stem cell research applications and the competitive environment in the market. It further points out the current trends in the global mesenchymal stem cells market and the various factors affecting the market growth. Profiles of some of the key players in the market have been included in the report. 

Mesenchymal stem cells, better known as MSC, refer to multipotent stem cells that can differentiate into various cell types such as chondrocytes, osteoblasts, adipocytes, myocytes, beta-pancreatic islet cells, and potentially, neuronal cells. MSCs are said to be immune-privileged and hence, are preferred during allogenic transplantation. The report offers an overview of the regenerative medicine and advanced therapies industry and segments the industry on the basis of product type and region. It also includes valuable information about major financial events and, partnerships and acquisitions. The report also points out the major opportunities for large pharmaceutical firms in the regenerative medicine and advanced therapies market. 

For more info, get a Sample PDF: http://www.researchmoz.us/enquiry.php?type=S&repid=301052 

The report provides an overview of various cell therapy products in early-stage and late-stage clinical development, including therapeutics developed for cardiovascular indication, wound care, autoimmune diseases, nervous system indication, diabetes, and spine and orthopaedics. Describing mesenchymal stem cells, the report lists down the major clinical sources of MSCs such as bone marrow-derived mesenchymal stem cells, adipose-derived mesenchymal stem cells, umbilical cord blood-derived mesenchymal stem cells, and stem cells derived from Wharton’s Jelly. Clinical application properties of each of these MSCs have been described in the report. 

The report further compiles information about the major diseases addressed by MSCs in current clinical trials such as neurodegenerative diseases, liver diseases, cardiovascular repair, autoimmune diseases, musculoskeletal diseases, spinal cord diseases, joint diseases, and wound healing. There has been increasing focus on immunological properties of MSCs. The report provides statistics regarding the percentage of MSCs clinical trials across different phases. 

Browse Report description and TOC:

http://www.researchmoz.us/mesenchymal-stem-cells-advances-and-applications-report.html 

Describing competitive landscape, the report profiles some of the key players in the global mesenchymal stem cells market such as Anterogen Co. Ltd., American Type Culture Collection Inc., BioCardia Inc., Apceth GmbH & Co. KG, BioRestorative Therapies Inc., BrainStorm Cell Therapeutics Inc., Bone Therapeutics S.A., Celprogen Inc., Cesca Therapeutics Inc., Cyagen Biosciences Inc., Cynata Therapeutics Ltd., Escape Therapeutics, Life Technologies Corporation, Lonza Group Ltd., Medipost Co. Ltd., NuVasive Inc., Mesoblast Ltd., Octa Therapeutics Inc., Orthofix International N.V., and others. The report also provides detailed information about the market players including their product portfolio, pipeline products, and clinical trials. 

Related Reports:- 

Induced Pluripotent Stem Cell (iPSC) Industry 2015-16 

Over the next few years, iPSC research advances accelerated exponentially. 2013 was the first time in which clinical research involving transplant of iPSCs into humans was initiated, led by Masayo Takahashi of the RIKEN Center for Developmental Biology in Kobe, Japan. Dr. Takahashi and her team are investigating the safety of iPSC-derived cell sheets in patients with wet-type age-related macular degeneration. While the trial was initiated in 2013 and production of iPSCs from patients began at that time, it was not until August of 2014 that the first patient was implanted with retinal tissue generated using iPSCs derived from her own skin cells. 

Browse Full Report:

http://www.researchmoz.us/complete-2015-16-induced-pluripotent-stem-cell-ipsc-industry-report-report.html 

About Us 

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.


            

Kontaktdaten